The search for peripheral disease markers in psychiatry by genomic and proteomic approaches

• THE BIOMARKER DEFINITIONS WORKING GROUP: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. (2001) 69(3):89-95.
   PubMed Web of Science ®Google Scholar
• MILDVAN D, LANDAY A, DE GV, MACHADO SG, KAGAN J: An approach to the validation of markers for use in AIDS clinical trials. Clin. Infect. Dis. (1997) 24(5):764-774.
   PubMed Web of Science ®Google Scholar
• FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2(7):566-580.
   PubMed Web of Science ®Google Scholar
• ROLAN P, ATKINSON AJ Jr, LESKO LJ: Use of biomarkers from drug discovery through clinical practice: report of the ninth European federation of pharmaceutical sciences conference on optimizing drug development. Clin. Pharmacol. Ther. (2003) 73(4):284-291.
   PubMed Web of Science ®Google Scholar
• BAKER M: In biomarkers we trust? Nat. Biotechnol. (2005) 23(3):297-304.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR), (4th Edition). American Psychiatric Press, Inc., Washington, DC (2000).
   Google Scholar
• KATZ MM, HALBREICH UM, BOWDEN CL et al.: Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology (2002) 27(3):319-328.
   PubMed Web of Science ®Google Scholar
• KHAN A, LEVENTHAL RM, KHAN SR, BROWN WA: Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database. J. Clin. Psychopharmacol. (2002) 22(1):40-45.
   PubMed Web of Science ®Google Scholar
• LANDIN R, DEBROTA DJ, DEVRIES TA, POTTER WZ, DEMITRACK MA: The impact of restrictive entry criterion during the placebo lead-in period. Biometrics (2000) 56(1):271-278.
   PubMed Web of Science ®Google Scholar
• HIRSCHFELD RM: History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry (2000) 61(Suppl. 6):4-6.
   PubMed Web of Science ®Google Scholar
• DELGADO PL: Depression: the case for a monoamine deficiency. J. Clin. Psychiatry (2000) 61(Suppl. 6):7-11.
   PubMed Web of Science ®Google Scholar
• CONNOR TJ, LEONARD BE: Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. (1998) 62(7):583-606.
   PubMed Web of Science ®Google Scholar
• TICHOMIROWA MA, KECK ME, SCHNEIDER HJ et al.: Endocrine disturbances in depression. J. Endocrinol. Invest. (2005) 28(1):89-99.
   PubMed Web of Science ®Google Scholar
• JOHNSTON TG, KELLY CB, STEVENSON MR, COOPER SJ: Plasma norepinephrine and prediction of outcome in major depressive disorder. Biol. Psychiatry (1999) 46(9):1253-1258.
   PubMed Web of Science ®Google Scholar
• GURGUIS GN, VO SP, GRIFFITH JM, RUSH AJ: Platelet α2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Res. (1999) 89(2):73-95.
   PubMed Web of Science ®Google Scholar
• GURGUIS GN, VO SP, GRIFFITH JM, RUSH AJ: Neutrophil β(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur. J. Pharmacol. (1999) 386(2-3):135-144.
   PubMed Web of Science ®Google Scholar
• SCHIEPERS OJ, WICHERS MC, MAES M: Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(2):201-217.
   PubMed Web of Science ®Google Scholar
• TSAO CW, LIN YS, CHEN CC, BAI CH, WU SR: Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(5):899-905.
   PubMed Web of Science ®Google Scholar
• HOLSBOER F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology (2000) 23(5):477-501.
   PubMed Web of Science ®Google Scholar
• ISING M, KUNZEL HE, BINDER EB, NICKEL T, MODELL S, HOLSBOER F: The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(6):1085-1093.
   PubMed Web of Science ®Google Scholar
• ISING M, HORSTMANN S, KLOIBER S et al.: Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression – a potential biomarker? Biol. Psychiatry (2007) 62(1):47-54.
   PubMed Web of Science ®Google Scholar
• CONNOR TJ, LEONARD BE: Biological markers for depression. In: Handbook of Experimental Pharmacology. Antidepressants. Past, Present and Future. (Volume 157). Preskorn SH, Feighner JP, Stanga C, Ross R (Eds), Springer, New York, USA (2004):117-148.
   Google Scholar
• HORROBIN DF: Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot. Essent. Fatty Acids (1996) 55(1-2):3-7.
   PubMed Web of Science ®Google Scholar
• HORROBIN DF: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. (1998) 30(3):193-208.
   PubMed Web of Science ®Google Scholar
• ROSS BM, HUDSON C, ERLICH J, WARSH JJ, KISH SJ: Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry (1997) 54(5):487-494.
   PubMed Web of Science ®Google Scholar
• THOMAS EA, DEAN B, PAVEY G, SUTCLIFFE JG: Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl. Acad. Sci. USA (2001) 98(7):4066-4071.
   PubMed Web of Science ®Google Scholar
• ROSS BM, HUGHES B, KISH SJ, WARSH JJ: Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord. (2006) 8(3):265-270.
   PubMed Web of Science ®Google Scholar
• MAHADIK SP, KHAN MM, EVANS DR, PARIKH VV: Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophr. Res. (2002) 58(1):55-62.
   PubMed Web of Science ®Google Scholar
• SEEMAN P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 1(2):133-152.
   PubMed Web of Science ®Google Scholar
• JONSSON EG, KAISER R, BROCKMOLLER J, NIMGAONKAR VL, CROCQ MA: Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr. Genet. (2004) 14(1):9-12.
   PubMed Web of Science ®Google Scholar
• ILANI T, BEN SHACHAR D, STROUS RD et al.: A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. USA (2001) 98(2):625-628.
   PubMed Web of Science ®Google Scholar
• VOGEL M, PFEIFER S, SCHAUB RT et al.: Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology (2004) 50(4):305-310.
   PubMed Web of Science ®Google Scholar
• ANGELUCCI F, BRENE S, MATHE AA: BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry (2005) 10(4):345-352.
   PubMed Web of Science ®Google Scholar
• GRATACOS M, GONZALEZ JR, MERCADER JM, DE CID R, URRETAVIZCAYA M, ESTIVILL X: Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry (2007) 61(7):911-922.
   PubMed Web of Science ®Google Scholar
• SHIMIZU E, HASHIMOTO K, WATANABE H et al.: Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. (2003) 351(2):111-114.
   PubMed Web of Science ®Google Scholar
• HUANG TL, LEE CT: Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J. Psychiatry Res. (2006) 40(7):664-668.
   PubMed Web of Science ®Google Scholar
• PALOMINO A, VALLEJO-ILLARRAMENDI A, GONZALEZ-PINTO A et al.: Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. (2006) 86(1-3):321-322.
   PubMed Web of Science ®Google Scholar
• ZHANG XY, TAN YL, ZHOU DF et al.: Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J. Psychiatry Res. (2007) 41(12):997-1004.
   PubMed Web of Science ®Google Scholar
• GRILLO RW, OTTONI GL, LEKE R, SOUZA DO, PORTELA LV, LARA DR: Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatry Res. (2007) 41(1-2):31-35.
   PubMed Web of Science ®Google Scholar
• GAMA CS, ANDREAZZA AC, KUNZ M, BERK M, BELMONTE-DE-ABREU PS, KAPCZINSKI F: Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. (2007) 420(1):45-48.
   PubMed Web of Science ®Google Scholar
• CUNHA AB, FREY BN, ANDREAZZA AC et al.: Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. (2006) 398(3):215-219.
   PubMed Web of Science ®Google Scholar
• MACHADO-VIEIRA R, DIETRICH MO, LEKE R et al.: Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry (2007) 61(2):142-144.
   PubMed Web of Science ®Google Scholar
• SHIMIZU E, HASHIMOTO K, OKAMURA N et al.: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry (2003) 54(1):70-75.
   PubMed Web of Science ®Google Scholar
• LANG UE, HELLWEG R, GALLINAT J: BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology (2004) 29(4):795-798.
   PubMed Web of Science ®Google Scholar
• KAREGE F, BONDOLFI G, GERVASONI N, SCHWALD M, AUBRY JM, BERTSCHY G: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry (2005) 57(9):1068-1072.
   PubMed Web of Science ®Google Scholar
• AYDEMIR C, YALCIN ES, AKSARAY S et al.: Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(7):1256-1260.
   PubMed Web of Science ®Google Scholar
• BOCCHIO-CHIAVETTO L, ZANARDINI R, BORTOLOMASI M et al.: Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur. Neuropsychopharmacol. (2006) 16(8):620-624.
   PubMed Web of Science ®Google Scholar
• LEE BH, KIM H, PARK SH, KIM YK: Decreased plasma BDNF level in depressive patients. J. Affect. Disord. (2007) 101(1-3):237-244.
   Google Scholar
• KIM YK, LEE HP, WON SD et al.: Low plasma BDNF is associated with suicidal behavior in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31(1):78-85.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI K, NARITA N, SAKUTA R et al.: Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev. (2004) 26(5):292-295.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO K, IWATA Y, NAKAMURA K et al.: Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(8):1529-1531.
   PubMed Web of Science ®Google Scholar
• MERCADER JM, RIBASES M, GRATACOS M et al.: Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav. (2007) [Epub ahead of print].
   Google Scholar
• HASLER G, DREVETS WC, MANJI HK, CHARNEY DS: Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 29(10):1765-1781.
   PubMed Web of Science ®Google Scholar
• ANDERSON NL, ANDERSON NG: The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics (2002) 1(11):845-867.
   PubMed Web of Science ®Google Scholar
• BROWN PO, BOTSTEIN D: Exploring the new world of the genome with DNA microarrays. Nat. Genet. (1999) 21(1 Suppl.):33-37.
   PubMed Web of Science ®Google Scholar
• ANDERSON NL, MATHESON AD, STEINER S: Proteomics: applications in basic and applied biology. Curr. Opin. Biotechnol. (2000) 11(4):408-412.
   PubMed Web of Science ®Google Scholar
• ANGENENDT P: Progress in protein and antibody microarray technology. Drug Discov. Today (2005) 10(7):503-511.
   PubMed Web of Science ®Google Scholar
• PATTERSON SD, AEBERSOLD RH: Proteomics: the first decade and beyond. Nat. Genet. (2003) 33:311-323.
   PubMed Web of Science ®Google Scholar
• MIRNICS K, LEVITT P, LEWIS DA: Critical appraisal of DNA microarrays in psychiatric genomics. Biol. Psychiatry (2006) 60(2):163-176.
   PubMed Web of Science ®Google Scholar
• LE NICULESCU H, BALARAMAN Y, PATEL S et al.: Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2007) 144(2):129-158.
   Google Scholar
• TANG Y, LU A, ARONOW BJ, SHARP FR: Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann. Neurol. (2001) 50(6):699-707.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN M, WEINSTOCK-GUTTMAN B, NGUYEN LT et al.: In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. (2001) 116(2):213-219.
   PubMed Web of Science ®Google Scholar
• BOMPREZZI R, RINGNER M, KIM S et al.: Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. (2003) 12(17):2191-2199.
   PubMed Web of Science ®Google Scholar
• ACHIRON A, GUREVICH M, FRIEDMAN N, KAMINSKI N, MANDEL M: Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. (2004) 55(3):410-417.
   PubMed Web of Science ®Google Scholar
• HERSHEY AD, TANG Y, POWERS SW et al.: Genomic abnormalities in patients with migraine and chronic migraine: preliminary blood gene expression suggests platelet abnormalities. Headache (2004) 44(10):994-1004.
   PubMed Web of Science ®Google Scholar
• TANG Y, SCHAPIRO MB, FRANZ DN et al.: Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Downs syndrome. Ann. Neurol. (2004) 56(6):808-814.
   PubMed Web of Science ®Google Scholar
• TANG Y, GLAUSER TA, GILBERT DL et al.: Valproic acid blood genomic expression patterns in children with epilepsy – a pilot study. Acta Neurol. Scand. (2004) 109(3):159-168.
   PubMed Web of Science ®Google Scholar
• MOORE DF, LI H, JEFFRIES N et al.: Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation (2005) 111(2):212-221.
   PubMed Web of Science ®Google Scholar
• TANG Y, XU H, DU X et al.: Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. (2006) 26(8):1089-1102.
   PubMed Web of Science ®Google Scholar
• BOROVECKI F, LOVRECIC L, ZHOU J et al.: Genome-wide expression profiling of human blood reveals biomarkers for Huntingtons disease. Proc. Natl. Acad. Sci. USA (2005) 102(31):11023-11028.
   PubMed Web of Science ®Google Scholar
• KALMAN J, KITAJKA K, PAKASKI M et al.: Gene expression profile analysis of lymphocytes from Alzheimers patients. Psychiatr. Genet. (2005) 15(1):1-6.
   PubMed Web of Science ®Google Scholar
• SHARP FR, XU H, LIT L et al.: The future of genomic profiling of neurological diseases using blood. Arch. Neurol. (2006) 63(11):1529-1536.
   PubMed Web of Science ®Google Scholar
• VAWTER MP, FERRAN E, GALKE B, COOPER K, BUNNEY WE, BYERLEY W: Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr. Res. (2004) 67(1):41-52.
   PubMedGoogle Scholar
• VAWTER MP, ATZ ME, ROLLINS BL, COOPER-CASEY KM, SHAO L, BYERLEY WF: Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia. Hum. Genet. (2006) 119(5):558-570.
   PubMed Web of Science ®Google Scholar
• TSUANG MT, NOSSOVA N, YAGER T et al.: Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 133(1):1-5.
   Web of Science ®Google Scholar
• MIDDLETON FA, PATO CN, GENTILE KL et al.: Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2005) 136(1):12-25.
   Google Scholar
• ZVARA A, SZEKERES G, JANKA Z et al.: Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers. Dis. Markers (2005) 21(2):61-69.
   PubMed Web of Science ®Google Scholar
• BOWDEN NA, WEIDENHOFER J, SCOTT RJ et al.: Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr. Res. (2006) 82(2-3):175-183.
   PubMed Web of Science ®Google Scholar
• SEGMAN RH, SHEFI N, GOLTSER-DUBNER T, FRIEDMAN N, KAMINSKI N, SHALEV AY: Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. Mol. Psychiatry (2005) 10(5):500-513.
   PubMed Web of Science ®Google Scholar
• WONG ML, LICINIO J: Peripheral is central to the question. Mol. Psychiatry (2005) 10(5):421-422.
   PubMed Web of Science ®Google Scholar
• ZIEKER J, ZIEKER D, JATZKO A et al.: Differential gene expression in peripheral blood of patients suffering from post-traumatic stress disorder. Mol. Psychiatry (2007) 12(2):116-118.
   PubMed Web of Science ®Google Scholar
• WILDER RL: Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. (1995) 13:307-338.
   PubMed Web of Science ®Google Scholar
• RAISON CL, MILLER AH: When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry (2003) 160(9):1554-1565.
   PubMed Web of Science ®Google Scholar
• DE KLOET ER, JOELS M, HOLSBOER F: Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. (2005) 6(6):463-475.
   PubMed Web of Science ®Google Scholar
• ROKUTAN K, MORITA K, MASUDA K et al.: Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J. Med. Invest. (2005) 52(3-4):137-144.
   PubMed Web of Science ®Google Scholar
• MORITA K, SAITO T, OHTA M et al.: Expression analysis of psychological stress-associated genes in peripheral blood leukocytes. Neurosci. Lett. (2005) 381(1-2):57-62.
   PubMed Web of Science ®Google Scholar
• OHMORI T, MORITA K, SAITO T, OHTA M, UENO S, ROKUTAN K: Assessment of human stress and depression by DNA microarray analysis. J. Med. Invest. (2005) 52(Suppl.):266-271.
   PubMedGoogle Scholar
• BARON CA, LIU SY, HICKS C, GREGG JP: Utilization of lymphoblastoid cell lines as a system for the molecular modeling of autism. J. Autism Dev. Disord. (2006) 36(8):973-982.
   PubMed Web of Science ®Google Scholar
• HU VW, FRANK BC, HEINE S, LEE NH, QUACKENBUSH J: Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genomics (2006) 7:118.
   PubMed Web of Science ®Google Scholar
• WAN C, YANG Y, LI H et al.: Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J. Proteome Res. (2006) 5(11):3213-3216.
   PubMed Web of Science ®Google Scholar
• YANG Y, WAN C, LI H et al.: Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal. Chem. (2006) 78(11):3571-3576.
   PubMed Web of Science ®Google Scholar
• WAN C, LA Y, ZHU H et al.: Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids (2007) 32(1):101-108.
   PubMed Web of Science ®Google Scholar
• HOLMES E, TSANG TM, HUANG JT et al.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. (2006) 3(8):1420-1428.
   Web of Science ®Google Scholar
• HUANG JT, MCKENNA T, HUGHES C, LEWEKE FM, SCHWARZ E, BAHN S: CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects. J. Sep. Sci. (2007) 30(2):214-225.
   PubMed Web of Science ®Google Scholar
• TSANG TM, HUANG JT, HOLMES E, BAHN S: Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. (2006) 5(4):756-760.
   PubMed Web of Science ®Google Scholar
• PRABAKARAN S, WENGENROTH M, LOCKSTONE HE, LILLEY K, LEWEKE FM, BAHN S: 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J. Proteome Res. (2007) 6(1):141-149.
   PubMed Web of Science ®Google Scholar
• GLATT SJ, EVERALL IP, KREMEN WS et al.: Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl. Acad. Sci. USA (2005) 102(43):15533-15538.
   PubMed Web of Science ®Google Scholar
• CORBETT BA, KANTOR AB, SCHULMAN H et al.: A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol. Psychiatry (2007) 12(3):292-306.
   PubMed Web of Science ®Google Scholar
• DOMENICI E, PROKOPENKO I, WILLE D et al.: Identification of biomarkers for depression by multi analyte profiling of peripheral samples from case/control collections. Special Issue: XIV World Congress on Psychiatry Genetics (WCPG), Cagliari, Italy (2006). Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141(7):790.
   Google Scholar
• NICHOLSON AC, UNGER ER, MANGALATHU R, OJANIEMI H, VERNON SD: Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. Brain Res. Mol. Brain Res. (2004) 129(1-2):193-197.
   PubMedGoogle Scholar
• SULLIVAN PF, FAN C, PEROU CM: Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141(3):261-268.
   Web of Science ®Google Scholar
• IWAMOTO K, KATO T: Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist (2006) 12(4):349-361.
   PubMed Web of Science ®Google Scholar
• MIDDLETON FA, MIRNICS K, PIERRI JN, LEWIS DA, LEVITT P: Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. (2002) 22(7):2718-2729.
   PubMed Web of Science ®Google Scholar
• VAWTER MP, SHANNON WC, FERRAN E et al.: Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem. Res. (2004) 29(6):1245-1255.
   PubMed Web of Science ®Google Scholar
• BUCHSBAUM MS, CHRISTIAN BT, LEHRER DS et al.: D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. (2006) 85(1-3):232-244.
   PubMed Web of Science ®Google Scholar
• PALOTAS A, PUSKAS LG, KITAJKA K et al.: The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem. Res. (2004) 29(8):1563-1570.
   PubMed Web of Science ®Google Scholar
• KALMAN J, KITAJKA K, PAKASKI M et al.: Gene expression profile analysis of lymphocytes from Alzheimers patients. Psychiatr. Genet. (2005) 15(1):1-6.
   PubMed Web of Science ®Google Scholar
• KALMAN J, PALOTAS A, JUHASZ A et al.: Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression-evolution of antidepressants and the role of the “neuro-immune” system. Neurochem. Res. (2005) 30(11):1429-1438.
   PubMed Web of Science ®Google Scholar
• MAMDANI F, SEQUEIRA PA, FFRENCH-MULLEN J, BEAULIEU MM, TURECKI G: Gene expression in peripheral lymphocyte cells of patients with major depressive disorder treated with citalopram. 62nd Annual Scientific Convention of the Society of Biological Psychiatry. San Diego, USA (2007):41.
   Google Scholar
• ORESIC M, VIDAL-PUIG A, HANNINEN V: Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev. Mol. Diagn. (2006) 6(4):575-585.
   PubMed Web of Science ®Google Scholar
• DETTMER K, ARONOV PA, HAMMOCK BD: Mass spectrometry-based metabolomics. Mass. Spectr. Rev. (2007) 26(1):51-78.
   PubMed Web of Science ®Google Scholar
• GERMAN JB, GILLIES LA, SMILOWITZ JT, ZIVKOVIC AM, WATKINS SM: Lipidomics and lipid profiling in metabolomics. Curr. Opin. Lipidol. (2007) 18(1):66-71.
   PubMed Web of Science ®Google Scholar
• PAIGE LA, MITCHELL MW, KRISHNAN KR, KADDURAH-DAOUK R, STEFFENS DC: A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry (2007) 22(5):418-423.
   PubMed Web of Science ®Google Scholar
• KADDURAH-DAOUK R, MCEVOY J, BAILLIE RA et al.: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry (2007) [Epub ahead of print].
   PubMedGoogle Scholar
• BAIRD AE: The blood option: transcriptional profiling in clinical trials. Pharmacogenomics (2006) 7(2):141-144.
   PubMed Web of Science ®Google Scholar
• BURCZYNSKI ME, DORNER AJ: Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics (2006) 7(2):187-202.
   PubMed Web of Science ®Google Scholar
• GREENBERG DA: Microarrays, markers of disease, and the myth of “nonhypothesis-driven” research. Ann. Neurol. (2001) 50(6):695.
   PubMed Web of Science ®Google Scholar
• QIAN WJ, JACOBS JM, LIU T, CAMP DG, SMITH RD: Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell Proteomics (2006) 5(10):1727-1744.
   PubMed Web of Science ®Google Scholar
• BOSCHETTI E, LOMAS L, CITTERIO A, RIGHETTI PG: Romancing the “hidden proteome”, Anno Domini two zero zero seven. J. Chromatogr. A. (2007) 1153(1-2):277-290.
   Google Scholar
• VERNON SD, REEVES WC: The challenge of integrating disparate high-content data: epidemiological, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics (2006) 7(3):345-354.
   PubMed Web of Science ®Google Scholar
• NOLL R: The blood of the insane. Hist. Psychiatry (2006) 17(68):395-418.
   PubMed Web of Science ®Google Scholar
• LAUDER LINDSAY W: The histology of the blood in the insane. J. Physiol. Med. Mental Pathol. (1855) 1:78-93.
   Google Scholar
• MACPHAIL SR: Blood of the insane. In: A Dictionary of Psychological Medicine. (Volume 1), Tuke DH (Ed.), P Blakiston and Son, Philadelphia, USA (1892):135-140.
   Google Scholar
• GLADKEVICH A, KAUFFMAN HF, KORF J: Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry (2004) 28(3):559-576.
   PubMed Web of Science ®Google Scholar
• CHARNEY DS, BARLOW DH, BOTTERON K et al.: Neuroscience research agenda to guide development of a pathophysiologically based classification system. In: A Research Agenda for DSM-V. Kupfer DJ, First MB, Regier DA (Eds), American Psychiatric Publishing, Washington, DC, USA (2000):31-83.
   Google Scholar
• BARRETT JC, CARDON LR: Evaluating coverage of genome-wide association studies. Nat. Genet. (2006) 38(6):659-662.
   PubMed Web of Science ®Google Scholar
• COUZIN J, KAISER J: Genome-wide association. Closing the net on common disease genes. Science (2007) 316(5826):820-822.
   PubMed Web of Science ®Google Scholar
• MORLEY M, MOLONY CM, WEBER TM et al.: Genetic analysis of genome-wide variation in human gene expression. Nature (2004) 430(7001):743-747.
   PubMed Web of Science ®Google Scholar
• STRANGER BE, FORREST MS, CLARK AG et al.: Genome-wide associations of gene expression variation in humans. PLoS Genet. (2005) 1(6):695-704.
   Web of Science ®Google Scholar
• STRANGER BE, FORREST MS, DUNNING M et al.: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 315(5813):848-853.
   PubMed Web of Science ®Google Scholar
• HARIRI AR, WEINBERGER DR: Imaging genomics. Br. Med. Bull. (2003) 65:259-270.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf US Department of Health and Human Services, Food and Drug Administration. Innovation or Stagnation: Critical Path Opportunities Report (2006).
   Google Scholar
• http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf US Department of Health and Human Services, Food and Drug Administration. Innovation or Stagnation: Critical Path Opportunities List (2006).
   Google Scholar